Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era

JAMA. 2022 Sep 20;328(11):1102-1104. doi: 10.1001/jama.2022.12868.

Abstract

This cohort study examines the validity of the Kidney Donor Profile Index’s hepatitis C virus (HCV) penalty during the direct-acting antiviral era by comparing 5-year allograft survival between recipients of kidneys from HCV-RNA–positive donors vs HCV-RNA–negative donors.

Publication types

  • Comparative Study

MeSH terms

  • Allografts* / drug effects
  • Allografts* / virology
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Graft Survival* / drug effects
  • Hepacivirus
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Kidney Failure, Chronic* / surgery
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / methods
  • Retrospective Studies
  • Tissue Donors

Substances

  • Antiviral Agents